S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
Critical asset just had biggest fall on record (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: World markets are lower after China unveils 5% economic growth target for 2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Ohio foundation begins process to distribute millions in opioid settlement money
Closing prices for crude oil, gold and other commodities
S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
Critical asset just had biggest fall on record (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: World markets are lower after China unveils 5% economic growth target for 2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Ohio foundation begins process to distribute millions in opioid settlement money
Closing prices for crude oil, gold and other commodities
S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
Critical asset just had biggest fall on record (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: World markets are lower after China unveils 5% economic growth target for 2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Ohio foundation begins process to distribute millions in opioid settlement money
Closing prices for crude oil, gold and other commodities
S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
Critical asset just had biggest fall on record (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: World markets are lower after China unveils 5% economic growth target for 2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Ohio foundation begins process to distribute millions in opioid settlement money
Closing prices for crude oil, gold and other commodities

I-Mab (IMAB) Competitors

$1.71
-0.08 (-4.47%)
(As of 03/4/2024 ET)

IMAB vs. CTMX, MCRB, RENB, ORMP, SYRS, NKTR, VTGN, GBIO, ADAG, and SGMT

Should you be buying I-Mab stock or one of its competitors? The main competitors of I-Mab include CytomX Therapeutics (CTMX), Seres Therapeutics (MCRB), Renovaro Biosciences (RENB), Oramed Pharmaceuticals (ORMP), Syros Pharmaceuticals (SYRS), Nektar Therapeutics (NKTR), Vistagen Therapeutics (VTGN), Generation Bio (GBIO), Adagene (ADAG), and Sagimet Biosciences (SGMT). These companies are all part of the "pharmaceutical preparations" industry.

I-Mab vs.

I-Mab (NASDAQ:IMAB) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, community ranking, profitability, media sentiment and institutional ownership.

22.6% of I-Mab shares are owned by institutional investors. Comparatively, 51.1% of CytomX Therapeutics shares are owned by institutional investors. 22.1% of I-Mab shares are owned by company insiders. Comparatively, 6.9% of CytomX Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, CytomX Therapeutics had 4 more articles in the media than I-Mab. MarketBeat recorded 6 mentions for CytomX Therapeutics and 2 mentions for I-Mab. I-Mab's average media sentiment score of 1.43 beat CytomX Therapeutics' score of 0.29 indicating that I-Mab is being referred to more favorably in the media.

Company Overall Sentiment
I-Mab Positive
CytomX Therapeutics Neutral

CytomX Therapeutics has higher revenue and earnings than I-Mab.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
I-Mab$13.81M9.99-$363.53MN/AN/A
CytomX Therapeutics$53.16M3.45-$99.32M-$0.45-6.09

I-Mab currently has a consensus price target of $19.00, suggesting a potential upside of 1,011.11%. CytomX Therapeutics has a consensus price target of $2.73, suggesting a potential downside of 0.36%. Given I-Mab's stronger consensus rating and higher possible upside, analysts plainly believe I-Mab is more favorable than CytomX Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
I-Mab
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
CytomX Therapeutics
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33

I-Mab has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500.

CytomX Therapeutics received 316 more outperform votes than I-Mab when rated by MarketBeat users. Likewise, 66.43% of users gave CytomX Therapeutics an outperform vote while only 61.18% of users gave I-Mab an outperform vote.

CompanyUnderperformOutperform
I-MabOutperform Votes
52
61.18%
Underperform Votes
33
38.82%
CytomX TherapeuticsOutperform Votes
368
66.43%
Underperform Votes
186
33.57%

I-Mab has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -38.86%.

Company Net Margins Return on Equity Return on Assets
I-MabN/A N/A N/A
CytomX Therapeutics -38.86%N/A -12.68%

Summary

I-Mab beats CytomX Therapeutics on 9 of the 15 factors compared between the two stocks.


Get I-Mab News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMAB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMAB vs. The Competition

MetricI-MabPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$138.00M$6.70B$4.92B$7.55B
Dividend YieldN/A2.83%5.31%3.87%
P/E RatioN/A16.81266.6618.63
Price / Sales9.99224.262,964.1277.10
Price / CashN/A21.0832.8728.77
Price / Book0.345.124.494.46
Net Income-$363.53M$152.61M$112.81M$212.48M
7 Day Performance-7.57%1.91%1.21%0.46%
1 Month Performance-0.58%15.31%12.72%7.36%
1 Year Performance-61.66%7.49%13.31%7.60%

I-Mab Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CTMX
CytomX Therapeutics
2.2177 of 5 stars
$2.25
+36.4%
$2.73
+21.3%
+28.0%$150.73M$53.16M-5.00116High Trading Volume
MCRB
Seres Therapeutics
3.7983 of 5 stars
$1.14
+6.5%
$13.20
+1,057.9%
-78.4%$147.36M$7.13M-1.02431
RENB
Renovaro Biosciences
0 of 5 stars
$2.17
-1.4%
N/AN/A$144.74MN/A-3.1012Gap Down
ORMP
Oramed Pharmaceuticals
0.6385 of 5 stars
$3.58
+0.8%
N/A+51.9%$144.42M$2.70M-8.7312
SYRS
Syros Pharmaceuticals
4.4299 of 5 stars
$7.34
-2.0%
$12.50
+70.3%
+93.4%$154.65M$14.88M-1.96117Upcoming Earnings
NKTR
Nektar Therapeutics
4.4793 of 5 stars
$0.75
+11.9%
$3.33
+344.4%
-42.7%$143.08M$92.06M-0.48216Earnings Report
News Coverage
Gap Up
VTGN
Vistagen Therapeutics
0.8972 of 5 stars
$5.29
+5.0%
$19.00
+259.2%
-4.7%$142.94M$1.11M0.0037Short Interest ↑
Positive News
GBIO
Generation Bio
4.0604 of 5 stars
$2.36
+6.8%
$8.56
+262.6%
-32.8%$155.95MN/A-1.19150
ADAG
Adagene
2.9757 of 5 stars
$3.21
-5.0%
$5.00
+55.8%
+83.7%$140.69M$9.29M0.00248Gap Down
SGMT
Sagimet Biosciences
1.9397 of 5 stars
$7.39
+2.6%
$50.00
+576.6%
N/A$157.96M$2M0.009

Related Companies and Tools

This page (NASDAQ:IMAB) was last updated on 3/5/2024 by MarketBeat.com Staff